<DOC>
	<DOCNO>NCT00828620</DOCNO>
	<brief_summary>Molecular image positron emission tomography ( PET ) use [ 18F ] fluorodeoxyglucose ( FDG ) suggest early , sensitive marker tumour response anticancer drug monitoring change glucose metabolism tumour . Recently , FDG-PET show highly sensitive detect early response tumour . In study , investigator prospectively investigate role early FDG-PET ( day 7 week 6 ) outcome prediction .</brief_summary>
	<brief_title>Positron Emission Tomography - Computed Tomography ( PET-CT ) Cetuximab Project</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Histologically cytologically proven colorectal cancer Unresectable stage IV disease KRas wild type tumour Patients schedule undergo chemotherapy irinotecan cetuximab Prior abdominal/pelvic radiotherapy , surgery chemotherapy within 3 month prior inclusion study Poorly control diabetes Concomitant serious illness , uncontrolled angina pectoris , myocardial infarction , heart failure , uncontrolled hypertension , infection Symptomatic brain metastasis Pregnancy participant reproductive potential sexually active willing/able use medically appropriate contraception</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
</DOC>